GET DAILY SIGNALSLifeVantage (LFVN) Reports Q1 Fiscal 2027 Results: Revenue Falls 22%
Key Takeaways
- LifeVantage reported first-quarter fiscal 2027 net revenue of $37.1 million, down 22% from $47.6 million a year earlier.
- Adjusted earnings per share (EPS) came in at $0.05, below the consensus estimate of $0.08, while revenue also missed the roughly $41.45 million analysts expected.
- Adjusted EBITDA fell to $1.9 million, or 5.2% of revenue, from $3.9 million in the prior-year period.
- The company swung to a GAAP net loss of $0.2 million, or $0.02 per diluted share, versus net income of $2.2 million a year ago.
- Softer order volumes, smaller average order size, and weaker MindBody GLP-1 System sales drove the decline, partially offset by the LoveBiome product line acquired in October 2025.
- LifeVantage ended the quarter with $13.7 million in cash and no debt outstanding.
Earnings Context and Why It Matters
LifeVantage Corporation is a health and wellness company best known for its Protandim product line and, more recently, its MindBody GLP-1 System, which targets the glucagon-like peptide-1 pathway tied to appetite and metabolism. This quarterly report carries extra weight because it is the first since the company began transitioning its fiscal year and since new leadership outlined a strategic reset. Investors are closely watching whether the LoveBiome acquisition can offset persistent demand softness in the core direct-selling business and whether a declining active-account base can stabilize. With subscription revenue still representing more than 75% of the total, the durability of that recurring base remains a central focus of the story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
For the first quarter of fiscal 2027, ended September 30, 2026, LifeVantage reported net revenue of $37.1 million, a 22% decline from $47.6 million in the prior-year period. Revenue in the Americas fell 22.2% to $29.0 million, while the Asia-Pacific and Europe region declined 21.2% to $8.2 million, including a $0.4 million negative foreign-currency impact. From what I see, these regional trends highlight ongoing pressure across the business.
GAAP net loss was $0.2 million, or $0.02 per diluted share, compared with net income of $2.2 million, or $0.17 per diluted share, a year earlier. Adjusted non-GAAP net income was $0.6 million, or $0.05 per diluted share, down from $2.3 million, or $0.18 per diluted share. Both revenue and adjusted EPS fell short of consensus estimates of roughly $41.45 million and $0.08, respectively. I also reviewed this using Tickeron’s AI Daily Buy/Sell Signals for additional perspective on recent momentum.
Gross profit margin declined to 75.4% from 79.5%, reflecting higher inventory obsolescence expenses and elevated shipping and warehouse costs; excluding the MindBody-related inventory allowance, adjusted gross margin was 78.2%. Adjusted EBITDA was $1.9 million, or 5.2% of revenue, compared with $3.9 million, or 8.2%, a year ago. Management attributed the weakness primarily to lower order volumes, reduced average order size, and continued softness in MindBody GLP-1 System sales, partly offset by LoveBiome contributions.
How the Market Reacted
The market responded negatively to the results. Shares fell roughly 5.5% in after-hours trading to near $5.00 following the release, reflecting disappointment that both revenue and adjusted EPS missed analyst expectations. The stock had already been under pressure, declining about 14% year to date ahead of the report. Investor sentiment remains cautious as the company works through a leadership transition and a reset of its product and brand strategy. The combination of a shrinking active-account base, macro-driven pressure on consumer spending, and difficult year-over-year comparisons for the MindBody GLP-1 System has kept confidence subdued, even as the balance sheet remains debt-free and the recurring subscription mix stays above 75% of revenue.
What to Watch Going Forward
Looking ahead, several factors will shape LifeVantage's trajectory. First, the company is managing a fiscal-year transition, with an anticipated effective tax rate of approximately 20% to 25% for the six-month period ending December 31, 2026. This shift adds a layer of complexity to year-over-year comparisons that investors should keep in mind.
Second, the LoveBiome integration remains a key swing factor. Management has highlighted early momentum in the microbiome health business, but its ability to offset declines in the legacy product portfolio will be central to any revenue stabilization. The MindBody GLP-1 System also faces tough prior-year comparables and a competitive wellness landscape. One thing that stands out is how these elements could influence the back half of the year.
Finally, watch for progress on the operational reset outlined by leadership, including a review of selling, general, and administrative (SG&A) expenses, investment in a new e-commerce platform, and efforts to improve consultant and customer retention. A debt-free balance sheet with $13.7 million in cash and a $60 million share repurchase authorization provides financial flexibility, but sustained demand recovery will ultimately determine whether the business can return to growth in the back half of the fiscal year. I’m watching this closely as the integration unfolds.
Enhancing Research with AI Tools
When evaluating results like these, I often rely on Tickeron’s AI Screener to quickly scan for comparable names and technical setups. It allows me to apply filters for fundamentals, volatility, and AI signals in one place, which helps put the quarter into broader context without spending hours on manual work. The tool has become a regular part of my process for staying on top of smaller-cap health and wellness names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LFVN in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
LFVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where LFVN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LFVN's RSI Oscillator exited the oversold zone, 22 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 62 cases where LFVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LFVN as a result. In 83 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for LFVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 46 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for LFVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.957) is normal, around the industry mean (6.914). P/E Ratio (13.050) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.670) is also within normal values, averaging (8.458). Dividend Yield (0.038) settles around the average of (0.049) among similar stocks. P/S Ratio (0.432) is also within normal values, averaging (5.003).
The Tickeron SMR rating for this company is 57 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. LFVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of nutraceutical dietary supplement
Industry FoodMajorDiversified
Advertisement